Genovis AB represents values of innovation, expertise, and partnership in the field of biotechnology. The company is committed to providing cutting-edge solutions and technologies for protein research and drug development. With a strong focus on customer satisfaction, Genovis AB embraces a collaborative approach, working closely with researchers, pharmaceutical companies, and academic institutions. By offering advanced enzymes and tools for protein analysis and engineering, Genovis AB aims to facilitate breakthrough discoveries and enhance therapeutic development processes. Through continuous product improvement, knowledge sharing, and ethical practices, Genovis AB strives to make a positive impact in the scientific community and contribute to human health and well-being.

Genovis AB is primarily present in multiple countries and regions. Its global presence spans across North America, Europe, Asia-Pacific, and other international markets. With a strong foothold in Sweden, Genovis AB has expanded its operations across various European countries, such as Germany, France, and the United Kingdom. Moreover, the company has also established significant market presence in the United States and Canada, highlighting its commitment to the North American region. Additionally, Genovis AB is actively engaged in serving customers in the Asia-Pacific region, including countries like China, Japan, and Australia.

Genovis AB has achieved several significant milestones in its history. One of the most notable accomplishments was the development of innovative enzyme technologies for the biopharmaceutical industry. The company's unique products, such as SmartEnzymes™, have revolutionized the field by enabling efficient drug development and production processes. Genovis AB has also established successful collaborations with leading pharmaceutical companies, further strengthening its position in the market. With its continuous dedication to research and development, Genovis AB continues to make breakthroughs in enzymology, delivering cutting-edge solutions for the biotech sector.

Genovis AB, a renowned biotechnology company, has an interesting history and background. Established in 1999 and headquartered in Lund, Sweden, Genovis specializes in innovative solutions for the development and production of enzymes and enzyme-based products. They possess a deep expertise in protein engineering and biomarker identification, offering cutting-edge tools and technologies for researchers in the fields of drug discovery, diagnostics, and therapeutic development. Genovis is committed to providing advanced solutions, such as their well-known enzyme portfolio, GlyCLICK™ antibody labeling kits, and biomarker assay development services. Continuously expanding and emphasizing collaborations with scientific partners globally, Genovis AB remains at the forefront of biotechnology advancements.

The main competitors of Genovis AB in the market include Abcam plc, Merck KGaA, and Thermo Fisher Scientific Inc.

Genovis AB is primarily active in the biotechnology and life sciences industry.

The business model of Genovis AB focuses on providing innovative enzyme-based technologies and solutions for the biopharmaceutical industry. Genovis offers a wide range of products and services that enable efficient drug development and production processes. The company specializes in developing and manufacturing enzymes that facilitate the analysis, modification, and quality control of biologics such as antibodies and recombinant proteins. With a strong emphasis on research and development, Genovis continuously strives to deliver cutting-edge solutions that support the advancement of therapeutic drugs. Through its unique enzyme technologies, Genovis aims to contribute to improved health outcomes for patients worldwide.

The Genovis P/E ratio is 37.57.

The Genovis P/S ratio is 8.66.

The Quality Investing for Genovis is 6/10.

The expected Genovis revenue is 144.84 M SEK.

The expected Genovis profit is 33.39 M SEK.

Genovis AB is a leading biotech company that develops innovative solutions in the field of biology and proteomics. The company was founded in 1999 and is headquartered in Lund, Sweden. The business model of Genovis is divided into three main divisions: Enzymes, Tools, and Services. The Enzyme division focuses on the development and production of recombinant proteases, including glycosidases, hydrolases, proteases, and peptidases. These enzymes play an important role in many applications in proteomics and the production of biotherapeutics, such as glycan synthesis, peptide sequencing, and therapeutic protein production. Genovis' Tools division offers a wide range of tools and accessories for proteomics research and analysis. The products offered include antibiotics, buffer systems, reagents, and kit systems. These tools are specifically tailored to the needs of researchers and technicians working with protein characterization and analysis of biological samples. Genovis' Services division offers various services to both academic and commercial customers, including custom protease and glycosidase purification services, custom assay development and optimization, glycoconjugation services, and labeling services. The company places great emphasis on high quality and customer satisfaction. The company operates an intensive research and development department aimed at developing new and improved products and services to meet customer needs. Thanks to a strong patent and brand strategy, the company has been able to acquire various valuable patents and sell its products worldwide. An important highlight of Genovis is also its focus on sustainability and environmental protection. The company strives to minimize the environmental impact of its products and services and relies on innovative solutions to reduce its carbon footprint. Overall, Genovis AB has a strong competitive advantage in the biotech market and has a successful history of innovation and research. By combining enzymes, tools, and services, the company offers its customers a comprehensive range of products and services. Genovis' broad product range allows researchers and scientists to find the right solutions for their specific needs.

Genovis pays a dividend of 0 SEK distributed over payouts per year.

The dividend cannot currently be calculated for Genovis or the company does not pay out a dividend.

The ISIN of Genovis is SE0002485979.

The WKN of Genovis is A0Q4ER.

The ticker of Genovis is GENO.ST.

Over the past 12 months, Genovis paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Genovis is expected to pay a dividend of 0 SEK.

The current dividend yield of Genovis is .

Genovis pays a quarterly dividend. This is distributed in the months of .

Genovis paid dividends every year for the past 0 years.

For the upcoming 12 months, dividends amounting to 0 SEK are expected. This corresponds to a dividend yield of 0 %.

Genovis is assigned to the 'Health' sector.

To receive the latest dividend of Genovis from 3/30/2025 amounting to 0 SEK, you needed to have the stock in your portfolio before the ex-date on 3/30/2025.

The last dividend was paid out on 3/30/2025.

In the year 2024, Genovis distributed 0 SEK as dividends.

The dividends of Genovis are distributed in SEK.